Aβ42/40 ratios are higher in notable APP gene variants such as V717I and KM670/671NL (“Swedish APP” for HEK293). Given that CRISPR/Cas9 can fix mutations in brain cell genomes, it presents a promising treatment approach for AD. This evidence concerns the gene APP and Alzheimer disease.